Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

Osteoporosis International

Volumn 21, Issue 1, 2010, Pages 145-155

  Cotte F E ^a,b   Fardellone, P ^c   Mercier, F ^d   Gaudin, A F ^b   Roux, C ^e  

^a INSERM   (France)

^b GLAXOSMITHKLINE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d STAT PROCESS   (France)

^e Paris Descartes University ^*  (France)

Author keywords

Adherence; Bisphosphonates; Compliance; Osteoporosis; Persistence; Treatment regimen

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DENSITOMETRY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG PRESCRIPTIONS; EPIDEMIOLOGIC METHODS; FEMALE; FRANCE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES;

EID: 72449182642     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0930-1     Document Type: Article

References (47)

1. World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva, Switzerland
2. SA Vik DB Hogan SB Patten JA Johnson L Romonko-Slack CJ Maxwell 2006 Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults Drugs Aging 23 345 356 10.2165/00002512-200623040-00007 16732693 (Pubitemid 43830665)
3. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 10.1007/s00198-006-0322-8 1:CAS:528:DC%2BD2sXntVOlsrY%3D 17308956 (Pubitemid 47019996)
4. F Lekkerkerker JA Kanis N Alsayed G Bouvenot N Burlet D Cahall A Chines P Delmas RL Dreiser D Ethgen N Hughes JM Kaufman S Korte G Kreutz A Laslop B Mitlak V Rabenda R Rizzoli A Santora R Schimmer Y Tsouderos P Viethel JY Reginster 2007 Adherence to treatment of osteoporosis: a need for study Osteoporos Int 18 1311 1317 10.1007/s00198-007-0410-4 1:STN:280: DC%2BD2srjtVensw%3D%3D 17585359 (Pubitemid 47389473)
5. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf PK Wong 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359
6. PP Geusens CH Roux DM Reid WF Lems S Adami JD Adachi PN Sambrook KG Saag NE Lane MC Hochberg 2008 Drug insight: Choosing a drug treatment strategy for women with osteoporosis-an evidence-based clinical perspective Nat Clin Pract Rheumatol 4 240 248 10.1038/ncprheum0773 1:CAS:528:DC%2BD1cXltFOqtrg%3D 18398411 (Pubitemid 351638681)
7. AN Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216 10.1016/S0002-9343(03)00362-0 12947959 (Pubitemid 37338146)
8. JJ Caro KJ Ishak KF Huybrechts G Raggio C Naujoks 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 10.1007/s00198-004-1652-z 15167989 (Pubitemid 40064656)
9. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
10. SH Gehlbach JS Avrunin E Puleo R Spaeth 2007 Fracture risk and antiresorptive medication use in older women in the USA Osteoporos Int 18 805 810 10.1007/s00198-006-0310-z 1:STN:280:DC%2BD2s3mt1Sjtw%3D%3D 17206400 (Pubitemid 46684787)
11. AM Gallagher S Rietbrock M Olson TP van Staa 2008 Fracture outcomes related to persistence and compliance with oral bisphosphonates J Bone Miner Res 23 1569 1575 10.1359/jbmr.080510 18505366
12. DT Gold BC Martin JR Frytak MM Amonkar F Cosman 2007 A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis Curr Med Res Opin 23 585 594 10.1185/030079906X167615 1:CAS:528:DC%2BD2sXkt1Wku7Y%3D 17355739 (Pubitemid 46456906)
13. FJ Penning-van Beest JA Erkens M Olson RM Herings 2008 Loss of treatment benefit due to low compliance with bisphosphonate therapy Osteoporos Int 19 511 517 10.1007/s00198-007-0466-1 1:STN:280:DC%2BD1c7nvFWqtw%3D%3D 17874028
14. JA Sunyecz L Mucha O Baser CE Barr MM Amonkar 2008 Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization Osteoporos Int 19 1421 1429 10.1007/s00198-008-0586-2 1:STN:280: DC%2BD1crnvVensg%3D%3D 18351427
15. V Rabenda R Mertens V Fabri J Vanoverloop F Sumkay C Vannecke A Deswaef GA Verpooten JY Reginster 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 10.1007/s00198-007-0506-x 1:CAS:528:DC%2BD1cXltFyjurs%3D 17999022
16. M Rossini G Bianchi O Di Munno S Giannini S Minisola L Sinigaglia S Adami 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 914 921 10.1007/s00198-006-0073-6 1:STN:280: DC%2BD283osVKltg%3D%3D 16538553 (Pubitemid 43781506)
17. AJ Carr PW Thompson C Cooper 2006 Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey Osteoporos Int 17 1638 1644 10.1007/s00198-006-0166-2 1:CAS:528: DC%2BD28XhtVagsrrI 16896510 (Pubitemid 44477624)
18. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 10.1185/030079905X61875 1:CAS:528: DC%2BD2MXhtFKqu7zP 16197664 (Pubitemid 41368578)
19. JA Cramer NO Lynch AF Gaudin M Walker W Cowell 2006 The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France Clin Ther 28 1686 1694 10.1016/j.clinthera.2006.10.013 1:CAS:528:DC%2BD28XhtlartrvP 17157124 (Pubitemid 44838898)
20. P Fardellone A Gaudin F Cotte A Lafuma C Marchand A El Hasnaoui 2005 Comparison of the persistence of daily and weekly bisphosphonates in French female patients treated for osteoporosis J Bone Miner Res 20 S285 S286
21. F Bauss RC Schimmer 2006 Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis Ther Clin Risk Manag 2 3 18 1:CAS:528:DC%2BD28XhtlWltb3O 18360577
22. A Cooper J Drake E Brankin 2006 Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study Int J Clin Pract 60 896 905 10.1111/j.1742-1241.2006.01059.x 1:CAS:528:DC%2BD28XpvVemsLg%3D 16800837 (Pubitemid 44082279)
23. DT Gold W Safi H Trinh 2006 Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate Curr Med Res Opin 22 2383 2391 10.1185/030079906X154042 1:CAS:528:DC%2BD2sXhsVOlt7k%3D 17257452 (Pubitemid 46055201)
24. S Bouee A Charlemagne F Fagnani P Le Jeunne C Sermet F Naudin PJ Lancry 2004 Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy Joint Bone Spine 71 214 220 10.1016/S1297-319X(03)00158-1 15182793 (Pubitemid 38739132)
25. CJ Rosen MC Hochberg SL Bonnick M McClung P Miller S Broy R Kagan E Chen RA Petruschke DE Thompson AE de Papp 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151 10.1359/JBMR.040920 1:CAS:528:DC%2BD2MXptValtA%3D%3D 15619680
26. JS McCombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 10.1016/j.maturitas.2004.02.005 1:CAS:528:DC%2BD2cXltVCiu7g%3D 15207894 (Pubitemid 38781153)
27. E Brankin M Walker N Lynch T Aspray Y Lis W Cowell 2006 The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases Curr Med Res Opin 22 1249 1256 10.1185/030079906X112688 1:CAS:528:DC%2BD28XotlKgtLw%3D 16834823 (Pubitemid 44085576)
28. N Lynch M Walker W Cowell N Suppapanya T Hammerschmidt U Rigney 2005 An international comparison of the impact of dosing frequency on adherence with bisphosphonate therapy among postmenopausal women in the UK and Germany J Bone Miner Res 21 S180
29. S Silverman C Chesnut M Amonkar M Cziraky C Barr 2006 Improved persistence in women treated with once-monthly ibandronate versus weekly biphosphonates: a first look J Bone Miner Res 22 SU355
30. P Rosenbaum D Rubin 1983 The central role of the propensity score in observational studied for causal effects Biometrika 70 41 55 10.1093/biomet/70.1.41
31. FE Cotte F Mercier G De Pouvourville 2008 Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis Clin Ther 30 2410 2422 10.1016/j.clinthera.2008.12.019 19167600
32. J Adachi N Lynch H Middelhoven M Hunjan W Cowell 2007 The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review BMC Musculoskelet Disord 8 97 10.1186/1471-2474-8-97 17897451 (Pubitemid 350174654)
33. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023
34. J Blouin A Dragomir Y Moride LG Ste-Marie JC Fernandes S Perreault 2008 Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women Br J Clin Pharmacol 66 117 127 10.1111/j.1365-2125.2008.03178.x 1:CAS:528:DC%2BD1cXptVKis7c%3D 18460036 (Pubitemid 351822168)
35. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922 928 10.1007/s00198-006-0085-2 1:CAS:528:DC%2BD28XkvVCnurY%3D 16609824 (Pubitemid 43781507)
36. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe A Grauer D Cahall NB Watts 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 10.1210/jc.2006-1526 1:CAS:528:DC%2BD2sXksVSrsbc%3D 17244788 (Pubitemid 46556401)
37. K Briot P Ravaud P Dargent-Molina M Zylberman S Liu-Leage C Roux 2009 Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience Osteoporos Int 20 625 630 10.1007/s00198-008-0698-8 1:STN:280:DC%2BD1M7osVClsQ%3D%3D 18661089
38. S Adami G Isaia G Luisetto S Minisola L Sinigaglia R Gentilella D Agnusdei N Iori R Nuti 2006 Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study J Bone Miner Res 21 1565 1570 10.1359/jbmr.060715 1:CAS:528:DC%2BD28XhtFekt7zN 16995811 (Pubitemid 44484601)
39. JL Schneider HA Fink SK Ewing KE Ensrud SR Cummings 2008 The association of Parkinson's disease with bone mineral density and fracture in older women Osteoporos Int 19 1093 1097 10.1007/s00198-008-0583-5 1:STN:280: DC%2BD1cvosFyjtA%3D%3D 18301855
40. I Tsiropoulos M Andersen T Nymark J Lauritsen D Gaist J Hallas 2008 Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study Epilepsia 49 2092 2099 10.1111/j.1528-1167.2008.01640.x 18479399
41. F Formiga M Navarro E Duaso D Chivite D Ruiz JM Perez-Castejon A Lopez-Soto R Pujol 2008 Factors associated with hip fracture-related falls among patients with a history of recurrent falling Bone 43 941 944 10.1016/j.bone.2008.06.014 18656561
42. DH Solomon JN Katz JP Jacobs AM La Tourette J Coblyn 2002 Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice Arthritis Rheum 46 3136 3142 10.1002/art.10613 12483716 (Pubitemid 35453521)
43. A Crochard A El Hasnaoui D Pouchain D Huas I Arnulf J Krieger E Lainey P Le Jeunne D Leger S Schuck N Texier F Tison J Montplaisir 2007 Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study Mov Disord 22 791 797 10.1002/mds.21325 17230475 quiz 907 (Pubitemid 46800099)
44. O Chassany P Le-Jeunne M Duracinsky MS Schwalm M Mathieu 2006 Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease Value Health 9 39 46 10.1111/j.1524-4733.2006.00079.x 16441523
45. E Van Ganse L Laforest E Alemao G Davies S Gutkin D Yin 2005 Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study Curr Med Res Opin 21 1389 1399 10.1185/030079905X59139 16197657 (Pubitemid 41368570)
46. F Fagnani M German-Fattal 2003 Antibiotic prescribing patterns of French GPs for upper respiratory tract infections: impact of fusafungine on rates of prescription of systemic antibiotics Am J Respir Med 2 491 498 14719988
47. JA Cramer SL Silverman DT Gold 2007 Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis Curr Med Res Opin 23 2369 2377 10.1185/030079907X226311 1:CAS:528:DC%2BD2sXhtlektLzI 17711617 (Pubitemid 350033438)